Nab-paclitaxel and gemcitabine or FOLFIRINOX as first-line treatment in patients with unresectable adenocarcinoma of the pancreas: does sequence matter?

Ursula M. Vogl,Haleh Andalibi,Alexander Klaus,Laurenz Vormittag,Wolfgang Schima,Bettina Heinrich,Alice Kafka,Thomas Winkler,Ohler L

Nab-paclitaxel and gemcitabine or FOLFIRINOX as first-line treatment in patients with unresectable adenocarcinoma of the pancreas: does sequence matter?

2019

Ursula M. Vogl
Haleh Andalibi
Alexander Klaus
Laurenz Vormittag
Wolfgang Schima
Bettina Heinrich
Alice Kafka
Thomas Winkler
Ohler L

Background Locally advanced or metastatic adenocarcinoma of the pancreas remains - despite the implementation of new chemotherapy protocols - a disease with short overall survival (OS).

Keywords:

Metastatic adenocarcinoma
Nab-paclitaxel
Cancer research
Medicine
Gemcitabine
Pancreas
FOLFIRINOX
Adenocarcinoma
Chemotherapy
Surgical oncology
Pancreatic cancer

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations